Fusion Antibodies (LON:FAB) Shares Up 5.3% – Here’s Why

Fusion Antibodies plc (LON:FAB)’s stock price shot up 5.3% during mid-day trading on Tuesday . The company traded as high as GBX 13.50 and last traded at GBX 12.90. 927,426 shares were traded during trading, an increase of 97% from the average session volume of 471,367 shares. The stock had previously closed at GBX 12.25.

Fusion Antibodies Stock Up 5.3%

The firm has a market cap of £16.13 million, a price-to-earnings ratio of -8.60 and a beta of 1.22. The company has a debt-to-equity ratio of 92.42, a current ratio of 1.80 and a quick ratio of 2.36. The stock has a 50-day moving average of GBX 13.46 and a 200-day moving average of GBX 14.13.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.